Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically detailing changes in share interests for Mr. A P Witty.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific director's share transaction rather than corporate financial performance.
Material Changes
There are no material changes to the company's financial position reported in this filing. The only reported activity is a change in the beneficial interest of Mr. A P Witty, involving the acquisition of 735 shares via dividend re-investment and the exercise of an award over 10,665 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Mr. A P Witty acquired 735 Ordinary shares on July 31, 2009, through dividend re-investment at £11.486 per share.
- Mr. Witty exercised an award for 10,665 Ordinary shares under the Annual Incentive Plan on July 31, 2009.
- To meet tax liabilities from the award exercise, 4,388 shares were sold on August 3, 2009, at £11.55125 per share.
- The transaction was notified to the company and the Commission on August 3, 2009.